Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Injection in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Next Previous
Trial Profile

A Phase 1B, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Injection in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary)
  • Indications Diabetic retinopathy
  • Focus Adverse reactions
  • Acronyms HELIOS
  • Sponsors Ocular Therapeutix

Most Recent Events

  • 26 Nov 2024 According to an Ocular Therapeutix media release, data from the study will be presented at FLORetina ICOOR 2024
  • 05 Sep 2024 According to an Ocular Therapeutix media release, data from the study will be presented at retina meetings being held in Portugal and Spain in September 2024.
  • 10 Jul 2024 According to an Ocular Therapeutics media release, interim safety and efficacy results from this trial will be presented as the abstract in 42nd American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held July 17-20 in Stockholm, Sweden.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top